Skip to content

A prospective, multicenter, randomized, controlled clinical trial to evaluate the safety and efficacy of intervertebral fusion devices manufactured by Beijing Norcomed Biotechnology Corporation Ltd

A prospective, multicenter, randomized, controlled clinical trial to evaluate the safety and efficacy of intervertebral fusion devices manufactured by Beijing Norcomed Biotechnology Corporation Ltd

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074331
Enrollment
Unknown
Registered
2023-08-03
Start date
2017-08-04
Completion date
Unknown
Last updated
2023-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases requiring spinal fusion

Interventions

Experiment group:3D printing porous titanium alloy fusion cage
Control group:PEEK fusion cage

Sponsors

The third Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
23 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged between 18 and 75; 2. The soft tissue of the operation area meets the operation requirements; 3. Surgical treatment of single segment of the following diseases: spinal degeneration, traumatic instability; iatrogenic instability of spinal segment after intervertebral decompression; structural scoliosis; spinal canal stenosis, spinal deformity and other congenital diseases. 4. Those who did not participate in other clinical trials within 3 months; 5. Patients (or their legal representatives) volunteer to participate in clinical trials, read carefully and sign informed consent forms

Exclusion criteria

Exclusion criteria: 1. Obvious local or systemic severe infection; 2. Mental disorders or neuromuscular and vascular diseases that affect the effect of postoperative fixation; 3. Pregnant women of childbearing age (18-49 years old); 4. Patients whose surgical site is not covered by enough tissue; 5. Definite or suspected allergy to the metal material or foreign body used in the product; 6. Osteoporosis, osteomalacia or similar bone mineral density decreased significantly; 7. Systemic or metabolic diseases; 8. Serious heart and lung diseases: 9. Obesity may damage implants. 10. Patients are unwilling or unable to follow the instructions of postoperative treatment and / or rehabilitation programs; 11. Mental illness, substance abuse or alcohol abuse; there is no guarantee to quit smoking during fracture healing; 12. The existing bone mass is not enough to provide adequate support or fixation for the implant and affect bony fusion; 13. Spinal tumor, vertebral fracture; 14. Multiple spondylolisthesis, multi-stage spinal canal stenosis or intervertebral disc herniation need to be corrected by fusion; 15. The first operation failed and the revision or the second spinal fusion operation: 16. Those who are receiving radiotherapy: 17. Long-term use of drugs that affect bone and soft tissue healing (such as steroids, except methylprednisolone); 18. The use of growth factors or continuous use of sedative hypnotics and non-companion anti-inflammatory drugs for more than 3 months; 19. General health condition is poor, there are general anesthesia contraindications such as coronary heart disease and hypertension; 20. The researchers judged other conditions that were not suitable for selection (such as polio sequelae, etc.).

Design outcomes

Primary

MeasureTime frame
Effective rate of interbody fusion;

Secondary

MeasureTime frame
Improvement rate of JOA score;Loss rate of intervertebral space height;

Countries

CHINA

Contacts

Public ContactYONG SHEN

The third Hospital of Hebei Medical University

lance_slee@163.com+86 133 1453 6819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026